Arbutus Biopharma Corporation
ABUSHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeArbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. The company carries a $643.8M market cap, placing it firmly in the small-cap category. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.
Market Cap
$643.8M
Beta
0.76
P/E (TTM)
5.32
P/E (Fwd)
-25.41
EPS (TTM)
$0.79
EPS (Fwd)
$-0.17
ROE
89.6%
ROA
48.8%
Cash
$92.6M
Total Debt
$3.6M
Free CF
-$80.2M
52W Change
-6.0%
Annual Financials
Cash vs Debt
Where ABUS stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, ABUS finished 8.32% below its 150-day moving average ($4.57) and 7.30% below its 200-day moving average ($4.52). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ABUS overbought or oversold?
At the October 15, 2026 close, ABUS's RSI(14) was 28.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $92.6M in cash comfortably exceeding the $3.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$80.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of 89.6% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 48.8% further supports the picture of efficient asset utilization. Revenue has pulled back from $39.0M (2022) to $14.1M (2025), a 64% decline worth watching.
With cash comfortably exceeding debt, ABUS has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing ABUS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.